MRC Human Genetics Unit, MRC IGMM, University of Edinburgh, Edinburgh, Scotland, United Kingdom.
Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Edinburgh Centre, MRC IGMM, University of Edinburgh, Edinburgh, Scotland, United Kingdom.
Clin Cancer Res. 2021 Jun 1;27(11):3201-3214. doi: 10.1158/1078-0432.CCR-20-4068. Epub 2021 Mar 19.
The abundance and effects of structural variation at BRCA1/2 in tumors are not well understood. In particular, the impact of these events on homologous recombination repair deficiency (HRD) has yet to be demonstrated.
Exploiting a large collection of whole-genome sequencing data from high-grade serous ovarian carcinoma ( = 205) together with matched RNA sequencing for the majority of tumors ( = 150), we have comprehensively characterized mutation and expression at .
In addition to the known spectrum of short somatic mutations (SSM), we discovered that multi-megabase structural variants (SV) were a frequent, unappreciated source of disruption in these tumors, and we found a genome-wide enrichment for large deletions at the loci across the cohort. These SVs independently affected a substantial proportion of patients (16%) in addition to those affected by SSMs (24%), conferring HRD and impacting patient survival. We also detail compound deficiencies involving SSMs and SVs at both loci, demonstrating that the strongest risk of HRD emerges from combined SVs at both and in the absence of SSMs. Furthermore, these SVs are abundant and disruptive in other cancer types.
These results extend our understanding of the mutational landscape underlying HRD, increase the number of patients predicted to benefit from therapies exploiting HRD, and suggest there is currently untapped potential in SV detection for patient stratification.
BRCA1/2 中结构变异的丰度及其对肿瘤的影响尚不清楚。特别是,这些事件对同源重组修复缺陷(HRD)的影响尚未得到证实。
利用来自高级别浆液性卵巢癌(=205)的大量全基因组测序数据以及大多数肿瘤的匹配 RNA 测序(=150),我们全面描述了 处的突变和表达情况。
除了已知的短体细胞突变(SSM)谱外,我们发现多兆碱基结构变体(SV)是这些肿瘤中 破坏的一个频繁但未被认识到的来源,并且我们发现整个队列中 基因座的大片段缺失存在全基因组富集。这些 SV 除了受 SSM 影响的患者(24%)之外,还独立影响了相当一部分患者(16%),导致 HRD 并影响患者的生存。我们还详细描述了两个基因座的 SSM 和 SV 复合缺陷,表明在没有 SSM 的情况下,来自两个 和 基因座的复合 SV 会产生最强的 HRD 风险。此外,这些 SV 在其他癌症类型中也很丰富且具有破坏性。
这些结果扩展了我们对 HRD 基础下突变景观的理解,增加了预测受益于利用 HRD 的治疗的患者数量,并表明目前在 SV 检测方面还有未被挖掘的患者分层潜力。